Accelerating Innovation at Leica Biosystems

Life Sciences Overview -$14.5B TOTAL REVENUE 2021E cytiva PALL BECKMAN COULTER Life Sciences SCIEX Leica XIDT phenomenex INTEGRATED ONA TECHNOLOGIES MICROSYSTEMS aldevron MOLECULAR DEVICES By End-Market • Rese Increasing focus on genomic medicine By Geography HGM ROW W.EU Clinical Aca Ind. Applied All financial metrics reflect FY 2021E results from continuing operations; all pie chart percentages are % of 2021E revenues. • Vaccine, therapeutics & research in response to COVID-19 HGM investments in basic & applied research capacity Strong global brands with leading market positions DANAHER

View entire presentation